– USA, TX – Castle Biosciences, Inc. (Nasdaq: CSTL), a dermatologic diagnostics company providing personalized genomic information to inform treatment decisions, today announced the appointments of Kim Caple and Ellen Goldberg to its board of directors, effective immediately.
“We are pleased to welcome Kim and Ellen to Castle’s board of directors,” said CEO, Derek Maetzold. “As we continue to grow our business, while remaining focused on improving the lives of patients, we believe their proven leadership and experience will be highly complementary to our board.”
About Kim Caple
Kim Caple is currently vice president and general manager, Genetic Science Business, at Thermo Fisher Scientific. The Genetic Science Business comprises three business units that develop, manufacture and commercialize genetic analysis technologies that serve the healthcare, forensic, research, and pharmaceutical/biotechnology markets globally. From 2017 through mid-2020, Caple was VP and general manager for the capillary electrophoresis business unit, a part of the Genetic Science Business within Thermo Fisher Scientific. From 2015 through 2016, she was VP of clinical business at Affymetrix, responsible for microarray products serving the reproductive health and oncology clinical laboratory markets. Affymetrix was acquired by Thermo Fisher Scientific in 2016. Caple supported the integration of the Affymetrix business into a new microarray business unit within the Genetic Science Business of Thermo Fisher Scientific.
Caple has a Bachelor of Science in biology from Purdue University.
About Ellen Goldberg
Ellen Goldberg is the founder and president of CHORD Consulting, where she works with executives of innovative diagnostics companies to develop and commercialize novel products. She has focused her career on ground-breaking technologies in life-threatening and life-altering diseases. Previously, Goldberg was vice president of marketing at Crescendo Bioscience, where she launched Vectra DA®, a multi-biomarker blood test that enables treatment changes to improve outcomes in rheumatoid arthritis. Before Crescendo, Goldberg led marketing at Genomic Health, where she launched the Oncotype DX® Breast Cancer Assay, a standard of care test that empowers over 80,000 women annually to make more informed decisions about their treatment, and helped develop tests in colon cancer, prostate cancer and ductal carcinoma in situ (DCIS). Goldberg began her career as a strategy consultant with Booz Allen & Hamilton and developed new products at ALZA Corporation.
She has a Master of Science in chemistry and a Master of Business Administration from Stanford University and a Bachelor of Science in chemistry from Yale University. Goldberg is also a fellow of the Aspen Institute’s Health Innovators Fellowship Program.
About Castle Biosciences
Castle Biosciences is a commercial-stage dermatologic diagnostics company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently offers tests for patients with cutaneous melanoma (DecisionDx-Melanoma, DecisionDx-CMSeq), cutaneous squamous cell carcinoma (DecisionDx-SCC), suspicious pigmented lesions (DecisionDx DiffDx-Melanoma, myPath Melanoma), and uveal melanoma (DecisionDx-UM, DecisionDx-PRAME, and DecisionDx-UMSeq).
Castle also has active research and development programs for tests in other dermatologic diseases with high clinical need, including its development test to predict systemic therapy response in patients with moderate to severe psoriasis, atopic dermatitis, and related conditions. Castle Biosciences is based in Friendswood, Texas (Houston), and has laboratory operations in Phoenix. Additionally, in May of 2021, Castle acquired the myPath Melanoma laboratory in Salt Lake City.
For more information: https://www.castlebiosciences.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.